Defining benchmark outcomes for transsphenoidal surgery of pituitary adenomas: a multicenter analysis

  • Richard Drexler
  • Roman Rotermund
  • Timothy R Smith
  • John L Kilgallon
  • Jürgen Honegger
  • Isabella Nasi-Kordhishti
  • Paul A Gardner
  • Zachary C Gersey
  • Hussein M Abdallah
  • John A Jane
  • Alexandria C Marino
  • Ulrich J Knappe
  • Nesrin Uksul
  • Jamil A Rzaev
  • Evgeniy V Galushko
  • Ekaterina V Gormolysova
  • Anatoliy V Bervitskiy
  • Henry W S Schroeder
  • Márton Eördögh
  • Marco Losa
  • Pietro Mortini
  • Rüdiger Gerlach
  • Mohammed Azab
  • Karol P Budohoski
  • Robert C Rennert
  • Michael Karsy
  • William T Couldwell
  • Apio C M Antunes
  • Manfred Westphal
  • Franz L Ricklefs
  • Jörg Flitsch

Beteiligte Einrichtungen

Abstract

IMPORTANCE: Benchmarks aid in improve outcomes for surgical procedures. However, best achievable results that have been validated internationally for transsphenoidal surgery (TS) are not available.

OBJECTIVE: We aimed to establish standardized outcome benchmarks for TS of pituitary adenomas.

DESIGN: A total of 2685 transsphenoidal tumor resections from 9 expert centers in 3 continents were analyzed.

SETTING: Patients were risk stratified, and the median values of each center's outcomes were established. The benchmark was defined as the 75th percentile of all median values for a particular outcome. The postoperative benchmark outcomes included surgical factors, endocrinology-specific values, and neurology-specific values.

RESULTS: Of 2685 patients, 1149 (42.8%) defined the low-risk benchmark cohort. Within these benchmark cases, 831 (72.3%) patients underwent microscopic TS, and 308 (26.8%) patients underwent endoscopic endonasal resection. Of all tumors, 799 (29.8%) cases invaded the cavernous sinus. The postoperative complication rate was 19.6% with mortality between 0.0% and 0.8%. Benchmark cutoffs were ≤2.9% for reoperation rate, ≤1.9% for cerebrospinal fluid leak requiring intervention, and ≤15.5% for transient diabetes insipidus. At 6 months, benchmark cutoffs were calculated as follows: readmission rate: ≤6.9%, new hypopituitarism ≤6.0%, and tumor remnant ≤19.2%.

CONCLUSIONS: This analysis defines benchmark values for TS targeting morbidity and mortality and represents the best outcomes in the best patients in expert centers. These cutoffs can be used to assess different centers, patient populations, and novel surgical techniques. It should be noted that the benchmark values may influence each other and must be evaluated in their own context.

Bibliografische Daten

OriginalspracheEnglisch
ISSN0804-4643
DOIs
StatusVeröffentlicht - 01.09.2023

Anmerkungen des Dekanats

© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PubMed 37668325